Phase 1b/2 study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients (pts) with treatment-naïve (TN) or prior venetoclax (VEN)-exposed myeloid malignancies.
Year: 2025
Type: conference-abstract
Source: Journal of Clinical Oncology
Authors: Michael Francis Leahy, Shaun Fleming, Patricia Kropf, Chong Chua, Tapan M. Kadia, Caspian Oliai, John Kwan, Chun Yew Fong, Joshua Richmond, Paul Cannell, James Dugan, Maria R. Baer, Stephen Ting, Daniel Egan, Zi Chen, Qian Niu, Mingyu Li, Mohammad Ahmad, Hengbang Wang, Yifan Zhai
Institutions: Royal Perth Hospital, The Alfred Hospital, Monash University, Novant Health, Northern Health, The University of Texas MD Anderson Cancer Center, University of California, Los Angeles, UCLA Health, Westmead Hospital, The University of Melbourne, Austin Health, Sunshine Coast University Hospital, Fiona Stanley Hospital, University of Maryland, Baltimore, University of Maryland Marlene and Stewart Greenebaum Comprehensive Cancer Center, Eastern Health, Swedish Medical Center, Ascentage Pharma Group Inc. (United States)
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4410809394